和元生物
(688238)
| 流通市值：26.28亿 | | | 总市值：36.54亿 |
| 流通股本：4.67亿 | | | 总股本：6.49亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 183,867,467.02 | 113,061,626.56 | 59,574,128.09 | 204,805,008.26 |
| 营业收入 | 183,867,467.02 | 113,061,626.56 | 59,574,128.09 | 204,805,008.26 |
| 二、营业总成本 | 362,113,906.26 | 236,598,085.89 | 117,835,749.83 | 360,583,467.55 |
| 营业成本 | 224,217,415.61 | 140,547,604.52 | 71,976,427.14 | 218,223,594.88 |
| 税金及附加 | 4,322,834.12 | 2,590,041.67 | 1,161,320.01 | 2,124,048.18 |
| 销售费用 | 36,955,485.19 | 24,363,018.86 | 11,504,200.06 | 41,968,797.79 |
| 管理费用 | 57,187,290.42 | 39,945,546.77 | 19,964,548.56 | 63,548,680.82 |
| 研发费用 | 39,151,904.55 | 29,083,260.88 | 13,787,220.55 | 50,916,965.6 |
| 财务费用 | 278,976.37 | 68,613.19 | -557,966.49 | -16,198,619.72 |
| 其中:利息费用 | 5,762,650.03 | 3,849,977.67 | 1,781,031.96 | 6,829,497.86 |
| 其中:利息收入 | 5,711,297.37 | 3,971,731.48 | 2,343,929.06 | 23,112,140.3 |
| 加:公允价值变动收益 | - | - | 61,000 | 12,657.53 |
| 加:投资收益 | -1,301,680.84 | -633,589.86 | -460,954.89 | -1,169,202.25 |
| 资产处置收益 | 5,902,026.46 | 1,082,683.03 | -14,606.88 | 101,679.09 |
| 资产减值损失(新) | -27,304,773.61 | -348,452.63 | -559,134.22 | -13,299,401.55 |
| 信用减值损失(新) | 525,019.93 | 649,905.66 | 1,152,508.31 | -1,064,213.84 |
| 其他收益 | 11,689,465.56 | 9,508,057.15 | 7,147,841.94 | 15,750,926.82 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -188,736,381.74 | -113,277,855.98 | -50,934,967.48 | -155,446,013.49 |
| 加:营业外收入 | 23,969.29 | 23,968.58 | 23,967.35 | 99,419.9 |
| 减:营业外支出 | 140,927.02 | 110,927.02 | 5,764.52 | 257,015.42 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -188,853,339.47 | -113,364,814.42 | -50,916,764.65 | -155,603,609.01 |
| 减:所得税费用 | 1,396,072.08 | 237,645.77 | -8,617,994.37 | -27,789,914.59 |
| 六、净利润 | -190,249,411.55 | -113,602,460.19 | -42,298,770.28 | -127,813,694.42 |
| 持续经营净利润 | -190,249,411.55 | -113,602,460.19 | -42,298,770.28 | -127,813,694.42 |
| 归属于母公司股东的净利润 | -189,766,756.86 | -113,345,377.29 | -42,170,292.32 | -127,938,329.85 |
| 少数股东损益 | -482,654.69 | -257,082.9 | -128,477.96 | 124,635.43 |
| (一)基本每股收益 | -0.29 | -0.18 | -0.07 | -0.2 |
| (二)稀释每股收益 | -0.29 | -0.18 | -0.07 | -0.2 |
| 八、其他综合收益 | -986,052.14 | -2,452,339.41 | -438,211.74 | 372,939.21 |
| 归属于母公司股东的其他综合收益 | -986,052.14 | -2,452,339.41 | -438,211.74 | 372,939.21 |
| 九、综合收益总额 | -191,235,463.69 | -116,054,799.6 | -42,736,982.02 | -127,440,755.21 |
| 归属于母公司股东的综合收益总额 | -190,752,809 | -115,797,716.7 | -42,608,504.06 | -127,565,390.64 |
| 归属于少数股东的综合收益总额 | -482,654.69 | -257,082.9 | -128,477.96 | 124,635.43 |
| 公告日期 | 2024-10-24 | 2024-08-29 | 2024-04-29 | 2024-04-25 |
| 审计意见(境内) | | | | 标准无保留意见 |